Security Snapshot

MADRIGAL PHARMACEUTICALS - Common Stock Institutional Ownership

CUSIP: 55273G298

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026

Latest Period

Q1 2026

Institutions Reporting

3

Shares (Excl. Options)

108,616

Price

$27.70

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Portfolio coverage rank
0%
Share change
-8,327
Value change
-$201,372
Number of holders
3
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • 55273G298 - MADRIGAL PHARMACEUTICALS - Common Stock is tracked under CUSIP 55273G298.
  • 3 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 3 to 0 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $3,037,769 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 3 institutions filings for Q1 2026.

Open SEC evidence

Security key

55273G298

Latest holder period

Q1 2026

13F holders

3

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 3 institutional investors reported holding 108,616 shares of MADRIGAL PHARMACEUTICALS - Common Stock.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
40
Latest
Q1 2026
Rows shown
1-25 of 40
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 0 $0 -$3,018,769 0
2026 Q1 108,616 $3,037,769 -$201,372 $27.70 3
2025 Q4 116,943 $3,245,641 +$264,841 $27.76 4
2025 Q3 106,751 $3,006,106 -$304,787 $28.16 1
2025 Q2 117,937 $3,166,602 +$173,679 $26.85 2
2025 Q1 111,468 $2,694,170 -$230,705 $24.17 1
2024 Q4 121,519 $2,777,743 +$26,998 $22.85 2
2024 Q3 111,144 $2,841,953 +$1,477,839 $25.57 1
2024 Q2 58,004 $1,364,114 +$1,364,114 $23.47 3
2024 Q1 0 $0 -$497,444 0
2023 Q4 22,393 $497,444 -$292,901 $22.21 1
2023 Q3 36,147 $768,187 +$428,110 $21.25 2
2023 Q2 16,004 $366,661 -$222,645 $22.91 1
2023 Q1 25,722 $559,719 +$559,719 $21.76 1
2022 Q4 0 $0 -$30,000 0
2022 Q3 1,658 $30,000 +$30,000 $18.09 1
2022 Q2 0 $0 -$216,000 0
2022 Q1 9,486 $216,000 +$216,000 $22.77 1
2020 Q2 0 $0 -$14,000 0
2020 Q1 681 $14,000 -$59,000 $20.56 1
2019 Q4 3,479 $73,000 +$15,455 $20.82 2
2019 Q3 2,729 $54,000 -$574,000 $19.79 1
2019 Q2 31,469 $629,000 +$377,000 $20.06 2
2019 Q1 12,840 $249,000 $19.27 2
2018 Q4 2,729 $47,000 +$47,000 $17.22 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .